Class summary at a glance.

Every drug in the Aminoglycoside Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 8tracked in Part D
CY24 Part D spend: $53.3Mcombined across class
Total Rx claims: 1.0M710K unique beneficiaries
Generic mfrs (active): 41across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tobramycin

Brand: BETHKIS · 382K Part D claims (CY24) · 305K beneficiaries · First FDA approval: 1981-06-28

23 generic mfrs 562 plans require PA Discontinued

Low NADAC$0.600

→

Avg plan cost$6.13

Part D spend $32.8M 10× spread, current vs floor

Class share

62%

of class CY24 spend

View profile →

Gentamicin

Brand: Gentak · 604K Part D claims (CY24) · 401K beneficiaries · First FDA approval: 1982-09-07

11 generic mfrs 132 plans require PA

Low NADAC$0.783

→

Avg plan cost$1.11

Part D spend $19.0M 1× spread, current vs floor

Class share

36%

of class CY24 spend

View profile →

Amikacin

Brand: ARIKAYCE · 19K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2013-12-24

6 generic mfrs 346 plans require PA

Low NADAC$2.72

→

Avg plan cost$2.72

Part D spend $1.5M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Loteprednol and Tobramycin

Brand: Zylet · — Part D claims (CY24) · First FDA approval: 2004-12-14

1 generic mfrs 0 plans require PA

Low NADAC$64.50

→

Avg plan cost$64.50

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tobramycin Inhalation

— Part D claims (CY24) · First FDA approval: 2020-09-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Tobramycin Inhalation Solution

— Part D claims (CY24) · First FDA approval: 2019-05-14

Brand-only (no generics)

Low NADAC$1.07

→

Avg plan cost$1.07

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tobramycin Ophthalmic Solution

— Part D claims (CY24) · First FDA approval: 2019-04-19

Brand-only (no generics)

Low NADAC$1.02

→

Avg plan cost$1.02

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tobramycin Solution

Brand: Tobramycin · — Part D claims (CY24) · First FDA approval: 2024-01-01

Brand-only (no generics)

Low NADAC$1.07

→

Avg plan cost$1.07

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.